Soleo Health, a national provider of specialty home and alternate-site infusion services, has been selected by Roche’s Genentech to dispense two limited distribution drugs, Hemlibra and Ocrevus.
Hemlibra (emicizumab-kxwh), for patients with hemophilia A with factor VIII inhibitors, received approval from the Food and Drug Administration (FDA) in November 2017. Ocrevus (ocrelizumab) is used for patients with relapsing or primary progressive forms of multiple sclerosis and was approved by the FDA in March 2017.
Soleo Health reported it has clinical experience in treating patients with those conditions and the company’s clinical team has engaged in training and education for the delivery of the two medications. Licensed in 50 states, Soleo administers the patient care services and delivery of nine limited distribution drugs across multiple therapeutic classes.
The company’s proprietary clinical outcomes program, SoleMetrics, provides customized outcome data for physicians, health systems, accountable care organizations, payers, and manufacturers. The resource used by clinicians is designed to enhance the patient experience and improve clinical outcomes, leading to reductions in the total cost of care.
Hemlibra is a registered trademark of Chugai Pharmaceutical Co., Ltd. and Ocrevus is a registered trademark of Genentech.
(Source: Soleo Health)
